B³: Build a Better Biosketch

MUSC Office of Research Development

B^3: BUILD A BETTER BIOSKETCH

Components of the NIH Non-Fellowship Biosketch

Biosketch Noncompliance

Introduction to SciENcv

WHAT IS THE NIH BIOGRAPHICAL SKETCH?

The NIH biographical sketch (biosketch) is a component of a grant proposal that enables reviewers to evaluate the qualifications of the PI and scientific team that will be executing the research project.

WHAT DO REVIEWERS WANT TO SEE IN THE BIOSKETCH?

Are you qualified to do the job? (Personal Statement)

Do you have peer-reviewed publications relevant to the proposal? (Contributions to Science)

Do you have appropriate time/effort devoted to the project? (Personal Statement/Positions)

BIOSKETCH FORMATTING GUIDELINES AND SUGGESTIONS

FIVE-PAGE LIMIT

FONT SIZE
≥ 11 POINTS

RECOMMENDED TYPEFACE
ARIAL
HELVETICA
PALATINO LINOTYPE
GEORGIA

NOT ALLOWED
FIGURES
TABLES
GRAPHICS

BIOSKETCH CITATIONS

Allowed to cite up to 24 research products collectively within the personal statement and contributions to science sections.

These include:

- Published papers
- Audio or video products
- Conference proceedings (meeting abstracts, posters, presentations)
- Patents
- Data and research materials
- Databases
- Educational aids or curricula
- Instruments or equipment
- Protocols
- Software or netware
- Interventions

https://grants.nih.gov/grants/rppr/Guide-to-Categorizing-Products-in-RPPR-Sec-C_draft.pdf

BIOSKETCH FORMAT COMPLIANCE

NOT-OD-21-073

- Updates to Biosketch and Other Support format page
  - New changes introduced March 12, 2021 become effective on May 25, 2021
  - Required for applications and Research Performance Program Reports
  - Applications that include the previous biosketch format will not be withdrawn until January 25, 2022

- Updates support the need for the applicants and recipients to provide full transparency and disclosure of all research activities, foreign and domestic

OLD FORMAT

OMB No. 0925-0001 and 0925-0002 (Rev. 03/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME:

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE:

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY

A. Personal Statement

B. Positions and Honors

C. Contributions to Science

D. Additional Information: Research Support and/or Scholastic Performance

NEW FORMAT

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME:

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE:

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY

A. Personal Statement

B. Positions, Scientific Appointments, and Honors

C. Contributions to Science

A. PERSONAL STATEMENT

- Briefly describe why you are well-suited for your role(s) in this project
  - Previous training and research experience
  - Technical expertise
  - Your collaborators or scientific environment
- If applicable, can include factors that affected past productivity
  - E.g., family care responsibilities, illness, disability, active-duty military service, etc.
- Indicate whether you have published or created research products under a different name

A. PERSONAL STATEMENT CONTINUED

- Do not present or expand on material that should be described in other sections of the biosketch
- Past performance in related field
  - Can include ongoing and completed research projects from the past three years to which you want to draw reviewers' attention
- You may cite up to four peer-reviewed publications or research products that highlight your experience and qualifications for the project
- Figures, tables, or graphics are not allowed

A. PERSONAL STATEMENT SUGGESTIONS

- Market yourself – convey excitement and passion
- Write in the first-person voice
- Customize for each grant application (R01, R21, R25, T32, P20, etc.)
- Do not use this section to circumvent the proposal page limits

A. PERSONAL STATEMENT
EXAMPLE 1 – CAREER DEVELOPMENT

My long-term research goal is to improve outcomes for children with common, serious infections by developing methods to improve diagnostic accuracy and implementing these methods into clinical practice. The objective of the proposed research is to combine advanced statistical and NMR metabolomics methodologies to inform pathogen-detection in childhood pneumonia. This research proposes the use of novel methods to identify pathogens causing CAP in an ambulatory and inpatient population of children with different levels of disease severity. My previous work has focused on antibiotic resistance, empiric antibiotic choice, and imaging modality in managing CAP in children. I am uniquely positioned to accomplish the aims stated in this proposal as I have a strong foundation in molecular and cellular biology and epidemiological methodology and have outlined a strong training plan to gain expertise in NMR metabolomics and advanced statistical methodology. In addition, the CARPE DIEM study infrastructure including recruitment and sample collection for children with CAP that is being leveraged as part of this proposal is fully funded by the Gerber Foundation and the Ohio Governor's Fund. I am currently a full-time Assistant Professor in the Divisions of Hospital Medicine and Biostatistics and Epidemiology. I plan to continue to conduct research in infectious diseases in children, focusing on developing and improving diagnostic tools for children diagnosed with common infectious diseases, such as pneumonia, globally. A K01 award would provide me with the resources to conduct novel research in the area of etiology identification for pediatric pneumonia.

https://www.niaid.nih.gov/sites/default/files//K01-Lilliam-Ambroggio-Application.pdf

A. PERSONAL STATEMENT
EXAMPLE 2 – CAREER DEVELOPMENT

The execution of epidemiologic research to inform public health action is an incredibly complex and rewarding task that requires the input, collegial cooperation, and applied knowledge of several dedicated individuals. Beyond my formal education, I have participated in HIV epidemiology and outcomes research in nearly every capacity: as a data abstractor, an IRB liaison, a data manager and quality control officer, a protocol analyst and editor, a statistical analyst, an abstract and manuscript editor and author, and others. I have also received extensive training in epidemiologic methods and biostatistics, making my skillset particularly well suited to the task of analyzing observational data while also providing me a solid foundation on which to build my understanding of policy evaluation and econometrics. Because of this varied experience, both in the development of questions and in the execution of the steps necessary to answer them scientifically and disseminate the results through publication, I believe that I have demonstrated my abilities as a competent researcher and epidemiologist. I believe I have also demonstrated my capacity for productive research collaborations on closely related topics, including through the use of uniquely rich data sources and by availing myself of the expertise of leaders in the field. I am currently working with both the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and the Caribbean, Central and South American network for HIV epidemiology (CCASAnet) of the NIH-funded International epidemiologic Databases to Evaluate AIDS (IeDEA), and am therefore also experienced in working with longitudinal data from large, geographically diverse HIV-infected populations. I therefore feel that I am well positioned to leverage these opportunities to answer significant questions in the arena of health policy and make a meaningful contribution to improve the lives of those with HIV.

https://www.niaid.nih.gov/sites/default/files//K01-Rebeiro-Application.pdf

A. PERSONAL STATEMENT
EXAMPLE 3 – RESEARCH

I am an Associate Professor of Psychology, and my research is focused on neuropsychological changes associated with addiction. I have a broad background in psychology, with specific training and expertise in ethnographic and survey research and secondary data analysis on psychological aspects of drug addiction. As PI or co-Investigator on several university- and NIH-funded grants, I laid the groundwork for the proposed research by developing effective measures of disability, depression, and other psychosocial factors relevant to the aging substance abuser, and by establishing strong ties with community providers that will make it possible to recruit and track participants over time as documented in the following publications. In addition, I successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. The current application builds logically on my prior work. During 2015-2016, my career was disrupted due to family obligations. However, upon returning to the field, I immediately resumed my research projects and collaborations and successfully competed for NIH support. In summary, I have the expertise, leadership, training, expertise and motivation necessary to successfully carry out the proposed research project.

https://grants.nih.gov/grants/forms/biosketch.htm

A. PERSONAL STATEMENT
EXAMPLE 3 CONTINUED – RESEARCH

Ongoing and recently completed projects that I would like to highlight include:

R01 DA942367
Hunt (PI)
09/01/16-08/31/21
Health trajectories and behavioral interventions among older substance abusers

R01 MH922731
Merryle (PI), Role: co-investigator
12/15/17-11/30/22
Physical disability, depression and substance abuse in the elderly

R21 AA998075
Hunt (PI)
01/01/19-12/31/21
Community-based intervention for alcohol abuse

Citations:
Merryle, R.J. & **Hunt, M.C.** (2015). Independent living, physical disability and substance abuse among the elderly. Psychology and Aging, 23(4), 10-22.
Hunt, M.C., Jensen, J.L. & Crenshaw, W. (2018). Substance abuse and mental health among community-dwelling elderly. International Journal of Geriatric Psychiatry, 24(9), 1124-1135.
Hunt, M.C., Wiechelt, S.A. & Merryle, R. (2019). Predicting the substance-abuse treatment needs of an aging population. American Journal of Public Health, 45(2), 236-245. PMCID: PMC9162292
Merryle, R. & **Hunt, M.C.** (2020). Randomized clinical trial of cotinine in older nicotine addicts. Age and Ageing, 38(2), 9-23. PMCID: PMC9002364

https://grants.nih.gov/grants/forms/biosketch.htm

A. PERSONAL STATEMENT
EXAMPLE 4A - RESEARCH

Our laboratory has been intensely focused on understanding the pathogenesis of wound healing, using the liver as a model. Because wound healing in the liver ultimately leads to the clinical disease known as cirrhosis, this model is important clinically. In this model system, injury leads to activation of effector cells, which in the liver are hepatic stellate cells. Although a number of cell types have been implicated as putative fibrogenic cells in the liver (including circulating fibrocytes, portal fibroblasts, and even cells derived from epithelial to mesenchymal transition or EMT), stellate cells appear to be the primary mediators the fibrogenic response, ultimately leading to fibrosis and cirrhosis.

Early in my career, our laboratory was the first to fully recognize that hepatic stellate cells express smooth muscle α actin, defining them as liver specific myofibroblasts during their activation. Since then, our laboratory has highlighted stellate cell expression of additional smooth muscle specific proteins, further bolstering the notion that the stellate cell transitions to a myofibroblast phenotype. We have extensive experience with isolation and study of primary hepatic stellate cells. Along with other laboratories, we have also demonstrated that primary hepatic stellate cells isolated from rodents provide robust models of human in vivo disease. We have substantial expertise working with in vivo models of injury, fibrosis and hepatic wound healing. In aggregate, our work has shed new light not only on the cell biology of stellate cells, but also on important molecular pathways important in wound healing. Our most recent work has focused on the stellate cell cytoskeleton, its function in the fibrogenic process, and importantly in signaling pathways critical to stellate cell fibrogenesis. The topic of this grant, myocardin and mir-143/145, were also initially recognized by our laboratory as critical to the hepatic stellate cell/myofibroblast phenotype.

I am the Principal Investigator (PI) or Site PI of several awards that are relevant to this proposal.

NIH/NIDDK R01 DK113159 09/20/17-08/31/21
A Molecular Approach to the Pathogenesis of Portal Hypertension
Role: Principal Investigator

… continued on next slide

Keep this introductory paragraph the same (with updates if needed).

Change this type of paragraph out, depending on your role in the specific proposal.

List ongoing and completed research projects from the past three years that are relevant to the proposal (previously captured under Section D. Research Support).

A. PERSONAL STATEMENT
EXAMPLE 4A CONTINUED – RESEARCH

Gilead Sciences, Inc. GS-US-428-4194 04/23/19-06/30/22
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GS-9674 in non-cirrhotic subjects with primary sclerosing cholangitis
Role: Site PI

Intercept Pharmaceuticals Inc747-304 09/01/18-08/31/22
A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis
Role: Site PI

Galectin GR-MD-02 10/25/19-12/31/24
A phase 3 clinical trial to evaluate the safety and efficacy of belapectin (GR-MD-02) for the treatment of patients with NASH cirrhosis with clinical evidence of clinically significant portal hypertension without esophageal varices at baseline
Role: Site PI

Additionally, several relevant reviews highlight our experience in the fibrosis field.

1. **Rockey DC**. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clinical Gastroenterology and Hepatology 11:224–231, 2013. PMCID: PMC4151461.
2. **Rockey DC**, Bell PD, Hill JA. Fibrosis--a common pathway to organ injury and failure. New England Journal of Medicine. 2015; 372(12): 1138-49.
3. **Rockey DC**. Liver fibrosis reversion after suppression of hepatitis B virus. Clinics in Liver Disease 20:667-679, 2016. PMCID PMC6438202.
4. **Rockey DC**, Friedman SL. Fibrosis regression after eradication of hepatitis C virus - from bench to bedside. Gastroenterology. 2021 Jan 30:S0016-5085(21)00330-9.

List ongoing and completed research projects from the past three years that are relevant to the proposal (previously captured under Section D. Research Support).

You may cite up to four publications or research products that highlight your experience and qualifications for this project.

A. PERSONAL STATEMENT
EXAMPLE 4B - MENTOR

Throughout my career, I have been fundamentally committed to scientific discovery and to mentoring. My training has been in basic, translational, and clinical research, and I have been actively engaged in all 3 areas for the past 25 years. Further, for my entire career, I have been committed to all aspects of training and mentorship. I have served on numerous institutional (at UCSF, Duke, UTSW and MUSC) and national (AGA, AASLD, AAIM) committees focused on mentorship and training. I have been actively involved in MSTP and PSTP programs throughout my career. I am personally deeply committed to the development of the academic careers of trainees. During my career, I have been fortunate to have mentored over 120 students, residents, post-doctoral fellows, and junior faculty members. Each one of these individuals were trained in an inclusive and supportive environment where they conducted rigorous and unbiased research. Projects have encompassed a broad range of topics, including in both basic science research (fibrogenesis and portal hypertension related) and on clinical research (focused on clinical management strategies). I support my mentees in identifying and transitioning into careers that are aligned with their skills and interests. The vast majority of my mentees have and/or are pursuing a career in academic medicine and are working at academic medical centers. Our work has been published in nearly 300 peer-reviewed manuscripts. A brief summary of basic and clinical research is highlighted below.

Provide an overview of mentoring activities and accomplishments.

My laboratory-based research interests are centered around understanding the pathogenesis of wound healing, using the liver as a model. Since wound healing in the liver ultimately leads to the clinical disease known as cirrhosis, this model is important clinically. In this model system, injury leads to activation of effector cells, which then carry out the fibrogenic response, ultimately leading to fibrosis and cirrhosis. The classic effector cell is known as the hepatic stellate cell, the study of which we have leveraged to great benefit. The work has shed new light not only on the cell biology of effector cells in this process, but also on important molecular pathways important in wound healing. We have been active particularly in regulation of extracellular matrix synthesis, and pathways important in its synthesis. Recent work has begun to focus on the role of the cytoskeleton and its interaction with other elements in the cell in effecting a fibrogenic phenotype. Additionally, we have strived to understand the cell and molecular vascular response of the liver to injury. We have also demonstrated that the stellate cell exhibits a contractile phenotype at a cellular level, and such appears not only to function as liver specific pericyte that regulates sinusoidal blood flow, but also that functions as a contractile myofibroblast, causing tissue architectural distortion and thus increased intrahepatic vascular resistance typical of portal hypertension.

Describe research activities. Discuss research efforts in basic, clinical and translational arenas, if necessary.

My clinically-based investigation involves establishing management strategies for common gastrointestinal and liver diseases, with a general theme on contributing to the literature in a practice based-learning approach. That is, we take common clinical questions…

A. PERSONAL STATEMENT
EXAMPLE 4B CONTINUED – MENTOR

… and ask practical questions about these. Projects are often focused around how we may better practice medicine. The areas of focus in the luminal gastrointestinal tract include areas related to the appropriate usage of endoscopy, in particular, the management of gastrointestinal bleeding - including portal hypertensive bleeding, acute upper GI bleeding, and occult and chronic gastrointestinal bleeding. The focus areas in the liver include in the area of chronic liver disease, particularly in patients with complications of cirrhosis, including esophageal variceal bleeding, ascites, kidney injury, and hepatic encephalopathy. We have focused in particular on topics that lend themselves to lead to changes in clinical practice. The techniques used in this clinical work include the use of retrospective and prospective cohort studies, case-control studies, and randomized controlled trials.

The following grants represent projects in which trainees would engage in my laboratory and reflect my mentoring experience:

NIH/NIDDK R01 DK113159 09/20/17-08/31/21
A Molecular Approach to the Pathogenesis of Portal Hypertension
Role: Principal Investigator

NIH/NIDDK P30 DK123704 04/15/20-03/31/25
Digestive Disease Research Core Center (DDRCC)
Role: Principal Investigator

NIH/NIDDK U24 DK065176 Barnhart (PI) 09/03/13-06/30/23
Coordinating Center for the Drug Induced Liver Injury Network (DILIN)
Role: Subaward PI

NIH/NIAID K08 AI121348 Meissner (PI) 01/01/16-12/31/20
Elucidating Mechanisms of Treatment Relapse for Interferon-Free HCV Therapy
Role: Mentor

NIH/NIDDK K23 DK118200 Schreiner (PI) 07/01/18-06/30/23
Improving the Diagnosis of Liver Disease in Primary Care Patients with Abnormal Liver Function
Role: Mentor

Describe research activities. Discuss research efforts in basic, clinical and translational arenas, if necessary.

List ongoing and completed research projects from the past three years that are relevant to the proposal (previously captured under Section D. Research Support).

A. PERSONAL STATEMENT
EXAMPLE 4B CONTINUED – MENTOR

I have been fortunate to have mentored many students, residents, post-doctoral fellows, and junior faculty members and am fundamentally committed to mentoring. A few publications authored by students, residents, and/or postdoctoral fellows are highlighted below:

1. Weymouth N, Shi Z, **Rockey DC**. (2012) Smooth muscle α actin is specifically required for the maintenance of lactation. Dev. Biol., 363(1):1-14. PMCID: PMC4151467.
2. Shafiei MS, Lui S, **Rockey DC**. (2015) Integrin-linked kinase regulates endothelial cell nitric oxide synthase expression in hepatic sinusoidal endothelial cells. Liver Int., 35(4):1213-21. PMCID: PMC4258191.
3. Singh S, Liu S, **Rockey DC**. (2016) Caveolin-1 is upregulated in hepatic stellate cells but not sinusoidal endothelial cells after liver injury. Tissue Cell, 48(2):126-32. PMCID: PMC6475201
4. Schreiner AD, Moran WP, Zhang J, Kirkland EB, Heincelman ME, Schumann Iii SO, Mauldin PD, **Rockey DC**. (2018) Evaluation of liver test abnormalities in a patient-centered medical home: do liver test patterns matter? J. Investig. Med., 66(8):1118-1123. PMCID: PMC6482948.

You may cite up to four publications or research products that highlight your experience and qualifications for this project.

B. POSITIONS, SCIENTIFIC APPOINTMENTS, AND HONORS

- List in **reverse chronological order** all positions and scientific appointments, both domestic and foreign
  - Include affiliations with foreign entities or governments
  - Include titled academic, professional, or institutional appointments whether or not remuneration is received
  - Include appointments whether full-time, part-time, or voluntary (including adjunct, visiting, honorary, or consultant)

B. POSITIONS, SCIENTIFIC APPOINTMENTS, AND HONORS CONTINUED

- List any relevant academic and professional achievements and honors
  - Students, postdoctorates, and junior faculty
    - Scholarships
    - Traineeships
    - Fellowships
    - Development awards
  - Clinicians
    - Clinical licensures
    - Specialty board certifications
- Include memberships in any professional organizations

B. POSITIONS, SCIENTIFIC APPOINTMENTS, AND HONORS EXAMPLE 1

Positions and Scientific Appointments

2021– Present	Associate Professor, Department of Psychology, Washington University, St. Louis, MO
2020 – Present	Adjunct Professor, McGill University Department of Psychology, Montreal, Quebec, Canada
2018 – Present	NIH Risk, Adult Addictions Study Section, members
2015 – 2017	Consultant, Coastal Psychological Services, San Francisco, CA
2014 – Present	Board of Advisors, Senior Services of Eastern Missouri
2014 – 2021	Assistant Professor, Department of Psychology, Washington University, St. Louis, MO
2014 – 2015	Ad hoc reviewer, NIH Peer Review Committee: Psychobiology of Aging
2013 – 2014	Lecturer, Department of Psychology, Middlebury College, Middlebury, VT
2011 – Present	Associate Editor, Psychology and Aging
2009 – Present	Member, American Geriatrics Society
2009 – Present	Member, Gerontological Society of America
2009 – 2013	Fellow, Division of Intramural Research, National Institute of Drug Abuse, Bethesda, MD
2006 – Present	Member, American Psychological Association

Honors

2020	Award for Best in Interdisciplinary Ethnography, International Ethnographic Society
2019	Excellence in Teaching, Washington University, St. Louis, MO
2018	Outstanding Young Faculty Award, Washington University, St. Louis, MO

https://grants.nih.gov/grants/forms/biosketch.htm

B. POSITIONS, SCIENTIFIC APPOINTMENTS, AND HONORS
EXAMPLE 1 – REFORMATTED

Positions

2021– Present	Associate Professor, Department of Psychology, Washington University, St. Louis, MO
2020 – Present	Adjunct Professor, McGill University Department of Psychology, Montreal, Quebec, Canada
2014 – 2021	Assistant Professor, Department of Psychology, Washington University, St. Louis, MO
2013 – 2014	Lecturer, Department of Psychology, Middlebury College, Middlebury, VT
2009 – 2013	Fellow, Division of Intramural Research, National Institute of Drug Abuse, Bethesda, MD

Scientific Appointments

2018 – Present	NIH Risk, Adult Addictions Study Section, members
2015 – 2017	Consultant, Coastal Psychological Services, San Francisco, CA
2014 – Present	Board of Advisors, Senior Services of Eastern Missouri
2014 – 2015	Ad hoc reviewer, NIH Peer Review Committee: Psychobiology of Aging
2011 – Present	Associate Editor, Psychology and Aging
2009 – Present	Member, American Geriatrics Society
2009 – Present	Member, Gerontological Society of America
2006 – Present	Member, American Psychological Association

Honors

2020	Award for Best in Interdisciplinary Ethnography, International Ethnographic Society
2019	Excellence in Teaching, Washington University, St. Louis, MO
2018	Outstanding Young Faculty Award, Washington University, St. Louis, MO

https://grants.nih.gov/grants/forms/biosketch.htm

C. CONTRIBUTIONS TO SCIENCE

- The proposed contributions do not have to be related to the project proposed in the applications

- BRIEFLY describe up to five of your most significant contributions to science
  - Historical background that frames that scientific problem
  - Central finding
  - Influence and findings on the progress of science or the application of those findings to health or technology
  - Specific role in the described work

- Descriptions of contributions may include a mention of research products under development

- The description of each contribution should be no longer than one-half page, including citations

C. CONTRIBUTIONS TO SCIENCE CONTINUED

- You may cite up to FOUR publications/research products for each contribution
  - Peer-reviewed
  - Non peer-reviewed
  - Accepted for publication
  - **Use of hyperlinks and URLs to cite these items is not allowed**

- Investigators are allowed to provide a URL to a full list of their published work
  - Providing a URL to a list of published work is not required
  - The URL MUST be to a federal government website (.gov suffix)
    - NIH recommends using My Bibliography
  - The URL cannot be hyperlinked text

C. CONTRIBUTIONS TO SCIENCE
SUGGESTIONS

- Keep the narrative(s) short
  - Three-four sentences followed by up to four publications and/or other products

- Give some thought to the organization/categorization within each contribution
  - E.g., by chronological events, by disease area, by methodologic approach, by type of research product (abstracts, peer-reviewed pubs, patents, etc.).

- Once written, this entire section will only need minor updates
  - E.g., addition of new research products

- Use My Bibliography to format a list of published work
  - Ensure that the My Bibliography URL link is active
  - Regularly update your My Bibliography
  - Ensure the the URL on your biosketch links to your My Bibliography

C. CONTRIBUTIONS TO SCIENCE
EXAMPLE I

1. **Neurobiology of addiction.** Using neuroimaging techniques and pharmacologic probes, my research group has focused on investigating the underlying neurobiology of SUDs in an effort to identify new targets for therapeutic development. These studies have included use of real-time fMRI feedback to decrease nicotine craving and investigation of the relationship of neural correlates of impulsivity and relapse.
    a. Hanlon CA, Hartwell KJ, Canterberry M, Li X, Owens M, Lematty T, Prisciandaro JJ, Borckardt J, **Brady KT**, George MS. Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits. *Psychiatry Res.* 2013; 213(1):79-81. PMCID: PMC4093788.
    b. Prisciandaro JJ, Myrick H, Henderson S, McRae-Clark AL, **Brady KT**. Prospective associations between brain activation to cocaine and no-go cues and cocaine relapse. *Drug Alcohol Depend.* 2013; 131(1-2):44-9. PMCID: PMC3703628.
    c. Hanlon CA, Owens MM, Joseph JE, Zhu X, George MS, **Brady KT**, Hartwell KJ. Lower subcortical gray matter volume in both younger smokers and established smokers relative to non-smokers. *Addict Biol.* 2014; 21(1):185-95. PMCID: PMC4326619.
    d. Prisciandaro JJ, Joseph JE, Myrick H, McRae-Clark AL, Henderson S, Pfeifer J, **Brady KT**. The relationship between years of cocaine use and brain activation to cocaine and response inhibition cues. *Addiction.* 2014; 109(12):2062-70. PMCID: PMC4229403.

2. **Research processes.** As PD/PI of the MUSC Clinical and Translational Science Award (CTSA), I am interested in developing and sharing processes and innovations to facilitate the conduct of research. This includes development of tools to improve the informed consent process, use of the electronic health record to enhance clinical trial recruitment and feasibility testing, and systematic consideration of conflict of interest concerns.
    a. Carter RE, Sonne SC, **Brady KT**. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study. *BMC Med Res Methodol.* 2005; 5:11. PMCID: PMC1079860.
    b. Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Andreasen NC, **Brady KT**, Brent DA, Brzustowicz L, Carter CS, Eisenberg L, Goldman H, Javitt DC, Leibenluft E, Lieberman JA, Milrod B, Oquendo MA, Rosenbaum JF, Rush AJ, Siever LJ, Suppes P, Weissman MM, Roy MD, Scully JH, Jr., Yager J. Conflict of interest--an issue for every psychiatrist. *Am J Psychiatry.* 2009; 166(3):274. PMCID: PMC4430107.
    c. Sonne SC, Andrews JO, Gentilin SM, Oppenheimer S, Obeid J, **Brady K**, Wolf S, Davis R, Magruder K. Development and pilot testing of a video-assisted informed consent process. *Contemp Clin Trials.* 2013; 36(1):25-31. PMCID: PMC3769445.
    d. Sanderson IC, Obeid JS, Madathil KC, Gerken K, Fryar K, Rugg D, Alstad CE, Alexander R, **Brady KT**, Gramopadhye AK, Moskowitz J. Managing clinical research permissions electronically: A novel approach to enhancing recruitment and managing consents. *Clin Trials.* 2013; 10(4):604-11. PMCID: PMC4213063.

C. CONTRIBUTIONS TO SCIENCE
EXAMPLE 2

1. **Bacterial Invasion and Signaling in Human Gingival Epithelial Cells.** My initial studies conducted in the early 2000s were the first to identify the gingival epithelial cell **β**1 integrin receptor for *P. gingivalis'* surface protein "major fimbriae", which primarily facilitates the organism's attachment and subsequent internalization into the host cells. This research was also first to characterize the associated cellular downstream signaling and structural events that are key for *P. gingivalis'* entry into "primary gingival epithelial cells" which is the model system we have been using in our lab for two decades with great success to produce physiologically consistent data. This line of research resulted in several high-impact journal publications which significantly increased our initial understanding of *P. gingivalis'* molecular mechanisms of colonization in the oral epi-mucosal tissues. The novel molecular approach we employed in the identification of the epithelial cell receptor for the bacterial fimbrial binding/invasion into host cells (ref.1 below) was further applied by Fusobacterium *nucleatum* researchers to identify the FadA adhesion into to the host cells.

2. **Other Scientific Contributions of Importance to the Oral Bacteria Host Interaction Field.** My laboratory has been a pioneer in genetic labeling of "anaerobic bacteria" for Green Fluorescent Protein expression for studying host-bacteria interaction, as well as designing novel fluorescence-based flow-cytometry and microscopy imaging approaches to examine live intracellular bacterial trafficking and subsistence. Related publications were featured in *Nature Reviews Microbiology*, *JADA* (Journal of American Dental Research) and multiple times in the *NIDCR* main webpage science news. Similarly, we have participated in development of novel methods to study *in-situ* growth activities of fastidious organisms in the patient samples. In addition, my laboratory research has critically contributed to the recent conceptual development of molecular mechanisms linking oral bacterial infections with oral cancer. We also showed the epithelial-mesenchymal transition during the long-term infection with *P. gingivalis*. Collectively, these studies resulted in novel findings for the field of oral pathogen-epithelial cell interaction and largely increased understanding of the mechanisms of co-existence and evolution of virulence between opportunistic bacterial invaders and human epi-mucosal tissues. Below are selected example publications for those advances.

BIOSKETCH NONCOMPLIANCE

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute of Health
Center for Scientific Review
6701 Rockledge Drive
Bethesda, Maryland 20892
Tel: 301-435-0715

Dr. John Doe
Medical University of South Carolina
[Redacted Address]
Charleston, SC 29425

Dear Dr. Doe:,

THIS NOTE SERVES AS A WARNING AND NO ACTION IS REQUIRED AT THIS TIME.

During the review of your application entitled "Title Here [Redacted]", NIH staff and/or reviewers noted that one or more of the biosketches included in the application did not comply with the new biosketch format requirements (NOT-OD-15-032; http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-032.html). Applications with biosketches that do not follow the current guidelines for format and content are non-compliant. You should be mindful that non-compliance can have serious consequences. NIH may withdraw any application identified during the receipt, referral and review process that is not compliant with the instructions in the SF424 (R&R) Application Guide, the Funding Opportunity Announcement, and relevant NIH Guide Notices (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-095.html). Instructions for preparing a compliant biosketch can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-032.html.

Your current application will not be withdrawn. There is no need to correct your biosketch(s) at this time. Indeed, as stated in NOT-OD-13-030, https://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-030.html), you cannot submit updated biosketches after the submission of the grant application. **If you have any questions regarding this correspondence, please contact the Scientific Review Officer who managed review of your application; that information can be found in eRA Commons or at the end of the meeting roster on your summary statement.** Also, please feel free to contact anyone in this office, at the e-mail address provided below, if you need more clarification about implementation of this policy.

The Division of Receipt and Referral
csrdrr@mail.nih.gov

BIOSKETCH NONCOMPLIANCE

- More than 4 citations listed in the personal statement and/or contribution to science sections

- Contribution to science section (including references) spanned more than ½ page

SCIENCE EXPERTS NETWORK CURRICULUM VITAE (SciENcv)

- SciENcv is an online tool that helps researchers create a research profile that complies with the NIH biosketch format
- SciENcv biosketches can be downloaded in three formats: PDF, MS Word, and XML
- If the biosketch is made public, a URL will be provided to share with others

To access SciENcv:
NCBI Login Page: https://www.ncbi.nlm.nih.gov/account/

BEST PRACTICES

Personal Statement

- Tailor the statement to the grant mechanism
- Explain your role on the grant
- Include publications that are most important to the grant even if repetitive with the Contributions to Science section

Contributions to Science

- Highlight the impact of your work
- Double-check the publications link
- Include PMCID numbers
- List publications in reverse chronological order (most recent first) on your publications website

Overall

- Make sure that you are using the most current NIH form
- Comply with the biosketch format guidelines
- Be CONSISTENT
- Review your biosketch for spelling and grammar errors

ADDITIONAL RESOURCES

To access presentation or for further advice

- Email Kim Cannady at cannadyk@musc.edu or Carla Stipe at stipecar@musc.edu
- MUSC Office of Research Development: https://research.musc.edu/resources/ord
  - Biosketch Resources: https://horseshoe.musc.edu/research/ord/grant-writing-toolkit/biosketches

Other Resources

- NIH Biosketch Format Pages
  - https://grants.nih.gov/grants/forms/biosketch.htm
- NCBI Login
  - https://www.ncbi.nlm.nih.gov/account/
- NIH Research Products: Definitions, Examples, and Distinctions
  - https://grants.nih.gov/grants/rppr/Guide-to-Categorizing-Products-in-RPPR-Sec-C_draft.pdf
- Generate eRA Commons Username
  - Email ORSP Representative: Kim Dalrymple at dalrympl@musc.edu

B³: BUILD A BETTER BIOSKETCH

QUESTIONS?

Office of Research Development

SciENcv Tutorial



My NCBI retains user information and database preferences to provide customized services for many NCBI databases.

YouTube My NCBI Overview

My NCBI features include:

- Save searches & automatic e-mail alerts
- Display format preferences
- Filter options
- My Bibliography & NIH public access policy compliance
- SciENcv: a researcher biosketch profile service
- Highlighting search terms
- Recent activity searches & records for 6 months
- LinkOut, document delivery service & outside tool selections

NIH funded investigator?

Extramural NIH-funded investigators looking for NIH Public Access Compliance tools can sign in with either "eRA Commons" or "NIH Login". Use your eRA Commons credentials on the subsequent sign in page. Once signed in, navigate to the My Bibliography section.

Documentation for using these features is located in the Managing Compliance to the NIH Public Access Policy section of the NCBI Help Manual.

Information about the NIH Public Access Policy is located at https://publicaccess.nih.gov.

Account Troubleshooting FAQ

Expired email confirmation link message
Multiple My NCBI accounts

SciENcv TUTORIAL
CONTINUED



SciENcv TUTORIAL
CONTINUED



SciENcv TUTORIAL
CONTINUED



1. Enter a name for the new biosketch
2. Select a biosketch format
3. Select data source
4. Choose to make your profile public or private

SciENcv TUTORIAL CONTINUED

My NCBI » SciENcv » Test New

SciENcv: About | Using

Profile name: Test New [Edit]

Download: PDF Word XML

Profile type: NIH Biosketch (March 2021) NIH Biographical Sketch Instructions

Last Updated: 5 April 2021

Sharing: Private [Change]

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

NAME [Edit]
Cannady, Kimberly

Click here to link eRA Commons account

EDUCATION/TRAINING

(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
You have not listed any degree or training. Please add one.

A. Personal Statement [Edit statement]

You have not yet provided a personal statement.

Optional: You may identify up to four peer reviewed publications that specifically highlight your experience and qualifications for this project.

[Select citations]

You have not listed any citations.

SciENcv – EDUCATION/TRAINING

My NCBI » SciENcv » Test New

SciENcv: About | Using

Profile name: Test New [Edit]

Download: PDF Word XML

Profile type: NIH Biosketch (March 2021) NIH Biographical Sketch Instructions

Last Updated: 5 April 2021

Sharing: Privat

d Through 02/28/2023)

NAME [Edit]
Cannady, Kimberly

Click here to link eRA Com

EDUCATION/TRAI

(Begin with baccalaureate

ible.)

You have not listed any de

A. Personal Statement [Edit Statement]

You have not yet provided a personal statement.

Optional: You may identify up to four peer reviewed publications that specifically highlight your experience and qualifications for this project.

[Select citations]

You have not listed any citations.

Add new degree

* required field

This entry is Degree Training

School: *

City:

State/Province:

Country:

Degree:* Choose a degree

Field of Study:

From: MM YYYY To: MM YYYY *

Save Save & add another entry Cancel

SciENcv – PERSONAL STATEMENT



SciENcv provides "Markdown" syntax which allows you to add simple formatting to your personal statement

SciENcv – POSITIONS, SCIENTIFIC APPOINTMENTS AND HONORS

Add Position or Scientific Appointment

* required field

From: * YYYY To: YYYY (leave blank for present positions)

Position title: *

Organization: *

add a level

City: State:

Country:

Use this entry as the position title and current employment

Save | Save & add another entry | Cancel

Add honors

* required field

Honor: *

By Organization: *

Year: * YYYY To: YYYY *(optional, for date ranges)*

Save | Save & add another entry | Cancel

SciENcv – CONTRIBUTION TO SCIENCE

C. Contribution to Science [Done]

You can add up to 5 contributions. Drag and drop tabs to rearrange.

Add another contribution

1

Delete this contribution

Description edit

Citations [Select citations]

Please include up to four citations that are relevant to this contribution.

☐ Include link to complete list of published work in My Bibliography.
(Selecting this option will make the list public.)

SciENcv TUTORIAL
CONTINUED

Profile name: Test New [Edit]

Profile type: NIH Biosketch (March 2021) NIH Biographical Sketch Instructions

Last Updated: 5 April 2021

Sharing: Private [Change]

Download: PDF Word XML

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

NAME [Edit]
Cannady, Kimberly

Click here to link eRA Commons account

EDUCATION/TRAINING

(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)
You have not listed any degree or training. Please add one.

A. Personal Statement [Edit statement]

You have not yet provided a personal statement.

Optional: You may identify up to four peer reviewed publications that specifically highlight your experience and qualifications for this project.

[Select citations]

You have not listed any citations.